세계의 백신 보조제 시장 - 규모, 점유율, 동향, 예측 : 제품 유형별, 투여 경로별, 질환별, 용도별, 지역별(2025-2033년)

The global vaccine adjuvants market size reached USD 1,107.0 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 2,851.7 Million by 2033, exhibiting a growth rate (CAGR) of 10.53% during 2025-2033. Global vaccine adjuvants market is growing rapidly due to the rising incidence of infectious diseases, significant milestones in immunology and vaccine technology, the escalating awareness of rare disease, the increased interest in pandemic vaccination efforts among the unbuilt population, burgeoning government spending, and the need for effective vaccination for the elderly.

Vaccine Adjuvants Market Trends:

Advancements in Vaccine and Immunology Technology

Immunology has made significant strides in vaccine adjuvant development, with new adjuvants being both more effective and safer than previously thought. Technological progress allows to design adjuvants that can selectively increase immune response to an antigen, which significantly increased vaccines' capability to fight a wide range of pathogens around the world. Recently, in February 2024, AbbVie , and Tentarix Biotherapeutics revealed the multi-year strategic partnership to develop biologic candidates in oncology and immunology. The agreement is valued more than USD 64 million. The drug candidates will be developed to combine AbbVie's capabilities in oncology and immunology with Tentarix's proprietary Tentacles platform to discover and develop conditionally active, multi-specific biologics against one target in each branch of medicine. This will activate immune cells that can modulate disease pathways while reducing the safety concern, typically associated with non-specific treatment.

Rising Awareness and Understanding of Rare Diseases

The growing recognition for rare diseases has accelerated distinctive challenges in the vaccine development. This new awareness has piqued the interest in vaccine adjuvants that can be customized to the specific needs of various stakeholders. As regards to the European Union, they defined RDs as affecting less than 50 per 100,000 people in the European population. However, the American Orphan Drug Act, outpatient, defined RDs as affecting less than 200,000 people in the United States. Other definitions included one as low as 5 per 100,000 people in Congo, while the highest was 76 per 100,000 people in India . On average, RDs affects 40 in every 100,000 people in the world. Recently, the prevalence of Rare Diseases prevalence, based on 3,585 RDs, was between 3.5 to 5.9 percent of the world population, equaling 263 to 446 million individuals.

Global Push for Vaccinations Against Pandemic Threats

The fight against the threat of pandemics, exemplified by COVID-19, sparked an unprecedented global vaccination crusade, propelling the vaccine adjuvants market into the spotlight of priority public health concerns. Moreover, the key uses of vaccine adjuvants are enhancing immune response, vaccine stability, improving vaccine efficiency and reducing vaccines doses, which in turn is propelling the market growth. "There were 15,141 new weekly hospital admissions for COVID-19, according to the ABC news. That's about the same as in early April 2024, according to information from the Centers for Disease Control and Prevention (CDC). But it's not as high as the peak of 150,650 hospitalizations per week for the week of Jan. 22, 2022, during the omicron wave". In total, more than 6 million Americans have been hospitalized over the course of the pandemic, the CDC reports.

Vaccine Adjuvants Market Segmentation:

Breakup by Product Type:

• Adjuvant Emulsions
• Pathogen Components
• Particulate Adjuvants
• Combination Adjuvants
• Others

Adjuvant Emulsions accounts for the majority of the market share

The adjuvant emulsions segment is driven by the increasing demand for vaccines with enhanced efficacy and longer-lasting immunity. This interest stems from the ability of emulsion-based adjuvants to provoke a strong and broad immune response, making them ideal for use in vaccines against complex diseases such as influenza and COVID-19. The versatility of emulsion adjuvants, compatible with a wide range of antigens, further boosts their appeal. Additionally, advancements in nanotechnology have improved the delivery mechanisms of these adjuvants, increased their effectiveness while maintaining safety profiles. The ongoing research and development efforts aimed at optimizing emulsion formulations are crucial in meeting the growing vaccine adjuvants market demand, underscoring their pivotal role in future vaccine development strategies.

Breakup by Route of Administration:

• Oral
• Intramuscular
• Intranasal
• Subcutaneous
• Intradermal
• Others

Intramuscular represents the leading market segment

The intramuscular segment is driven by the increasing demand for vaccines that require deep tissue penetration for optimal efficacy, such as vaccines against influenza, tetanus, and COVID-19. This method is preferred for its ability to deliver larger volumes of a vaccine directly into the muscle, where there is a rich blood supply, facilitating a stronger and quicker immune response. Additionally, the intramuscular route is favored for its relative ease of administration, minimal discomfort, and lower risk of adverse reactions compared to other methods, making it a widely accepted practice in vaccination programs globally. The consistency in vaccine absorption rates and the extensive historical data supporting its effectiveness further bolster its adoption, underlining the segment's growth.

Breakup by Diseases:

• Cancer
• Infectious Diseases
• Others

Infectious diseases accounts for the majority of the market share

The infectious diseases segment is driven by the increasing prevalence of global pandemics and emerging infectious threats, which highlight the critical need for effective vaccines. Factors such as international travel, urbanization, and climate change contribute to the spread of infectious diseases, necessitating rapid development and deployment of vaccines with potent adjuvants. The segment's growth is further fueled by governmental and international initiatives to combat infectious diseases, alongside significant investments in research and development. Moreover, public awareness and healthcare infrastructure improvements play essential roles in supporting vaccination programs, thereby enhancing the demand for innovative vaccine adjuvants tailored to combat these diseases effectively.

Breakup by Application:

• Research
• Commercial

Research represents the leading market segment

The research segment in the vaccine adjuvants market is driven by the increasing demand for more efficacious vaccines against a broader range of pathogens, including emerging and re-emerging infectious diseases. This need is coupled with a growing understanding of the immune system's complexities, prompting scientists to explore novel adjuvant formulations that can elicit stronger and more durable immune responses. Additionally, the push for personalized medicine and vaccines tailored to individual genetic makeups fuels the exploration of innovative adjuvants. Advances in biotechnology and nanotechnology further drive this segment, enabling the development of next-generation adjuvants that can be precisely engineered to enhance vaccine effectiveness while minimizing side effects.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

North America leads the market, accounting for the largest vaccine adjuvants market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for vaccine adjuvants.

The North America's vaccine adjuvants are expected to dominate the market due to extensive investment in researching and developing (R&D) vaccines that are aimed at tackling a wide range of infectious illnesses and rising health concerns from both the public and private sectors. The region has the advantage of a rapid approval process for vaccines, which encourages drug companies to expand and boost investments into adjuvant technologies. Furthermore, North America has many of the top research centers superiority and frequent collaboration with the biotech sector. As a result, it is the field of medical technology and innovation. In addition, to improve the effectiveness of vaccines, adjuvants, are used with greater awareness of the importance of boosting the effectiveness and safety of vaccines, driving market expansion in North America.

Competitive Landscape:

• The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the vaccine adjuvants industry include Adjuvatis, Agenus Inc., Croda International Plc, CSL Limited, Dynavax Technologies, InvivoGen, Novavax Inc., OZ Biosciences, Phibro Animal Health Corporation, SEPPIC, SPI Pharma, etc.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

• Key players in the vaccine adjuvants market are actively engaging in research and development activities to introduce innovative and more effective adjuvant formulations. These efforts are aimed at enhancing the immune response elicited by vaccines, ensuring broader and more durable protection against a variety of infectious diseases and for therapeutic vaccines targeting chronic conditions such as cancer. For instance, in February 2022, Novavax Inc. announced positive interim results from their Phase 3 clinical trial evaluating their COVID-19 vaccine candidate, NVX-CoV2373, combined with their proprietary adjuvant, Matrix-M. The results showed strong efficacy against COVID-19, demonstrating an overall efficacy of over 90%. Collaborations and partnerships are a common strategy, uniting expertise from academic institutions, research organizations, and biotechnology firms to accelerate the development of next-generation adjuvants. Furthermore, these companies are investing in advanced technologies and exploring novel adjuvant substances, including synthetic molecules and natural compounds, to improve vaccine efficacy and safety profiles. Regulatory compliance and the pursuit of fast-track approval processes are also critical, as companies navigate the complex landscape to bring their innovations to market. Through these actions, key players are significantly contributing to the dynamic growth and evolution of the global vaccine adjuvants market.

Key Questions Answered in This Report

• 1.What was the size of the global vaccine adjuvants market in 2024?
• 2.What is the expected growth rate of the global vaccine adjuvants market during 2025-2033?
• 3.What are the key factors driving the global vaccine adjuvants market?
• 4.What has been the impact of COVID-19 on the global vaccine adjuvants market?
• 5.What is the breakup of the global vaccine adjuvants market based on the product type?
• 6.What is the breakup of the global vaccine adjuvants market based on route of administration?
• 7.What is the breakup of the global vaccine adjuvants market based on the diseases?
• 8.What is the breakup of the global vaccine adjuvants market based on the application?
• 9.What are the key regions in the global vaccine adjuvants market?
• 10.Who are the key players/companies in the global vaccine adjuvants market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Vaccine Adjuvants Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product Type

• 6.1 Adjuvant Emulsions
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Pathogen Components
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Particulate Adjuvants
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Combination Adjuvants
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Others
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast

7 Market Breakup by Route of Administration

• 7.1 Oral
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Intramuscular
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Intranasal
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Subcutaneous
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Intradermal
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast
• 7.6 Others
  • 7.6.1 Market Trends
  • 7.6.2 Market Forecast

8 Market Breakup by Diseases

• 8.1 Cancer
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Infectious Diseases
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Others
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Application

• 9.1 Research
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Commercial
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 United States
    • 10.1.1.1 Market Trends
    • 10.1.1.2 Market Forecast
  • 10.1.2 Canada
    • 10.1.2.1 Market Trends
    • 10.1.2.2 Market Forecast
• 10.2 Asia-Pacific
  • 10.2.1 China
    • 10.2.1.1 Market Trends
    • 10.2.1.2 Market Forecast
  • 10.2.2 Japan
    • 10.2.2.1 Market Trends
    • 10.2.2.2 Market Forecast
  • 10.2.3 India
    • 10.2.3.1 Market Trends
    • 10.2.3.2 Market Forecast
  • 10.2.4 South Korea
    • 10.2.4.1 Market Trends
    • 10.2.4.2 Market Forecast
  • 10.2.5 Australia
    • 10.2.5.1 Market Trends
    • 10.2.5.2 Market Forecast
  • 10.2.6 Indonesia
    • 10.2.6.1 Market Trends
    • 10.2.6.2 Market Forecast
  • 10.2.7 Others
    • 10.2.7.1 Market Trends
    • 10.2.7.2 Market Forecast
• 10.3 Europe
  • 10.3.1 Germany
    • 10.3.1.1 Market Trends
    • 10.3.1.2 Market Forecast
  • 10.3.2 France
    • 10.3.2.1 Market Trends
    • 10.3.2.2 Market Forecast
  • 10.3.3 United Kingdom
    • 10.3.3.1 Market Trends
    • 10.3.3.2 Market Forecast
  • 10.3.4 Italy
    • 10.3.4.1 Market Trends
    • 10.3.4.2 Market Forecast
  • 10.3.5 Spain
    • 10.3.5.1 Market Trends
    • 10.3.5.2 Market Forecast
  • 10.3.6 Russia
    • 10.3.6.1 Market Trends
    • 10.3.6.2 Market Forecast
  • 10.3.7 Others
    • 10.3.7.1 Market Trends
    • 10.3.7.2 Market Forecast
• 10.4 Latin America
  • 10.4.1 Brazil
    • 10.4.1.1 Market Trends
    • 10.4.1.2 Market Forecast
  • 10.4.2 Mexico
    • 10.4.2.1 Market Trends
    • 10.4.2.2 Market Forecast
  • 10.4.3 Others
    • 10.4.3.1 Market Trends
    • 10.4.3.2 Market Forecast
• 10.5 Middle East and Africa
  • 10.5.1 Market Trends
  • 10.5.2 Market Breakup by Country
  • 10.5.3 Market Forecast

11 SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Adjuvatis
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
  • 15.3.2 Agenus Inc.
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
  • 15.3.3 Croda International Plc
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
    • 15.3.3.3 Financials
    • 15.3.3.4 SWOT Analysis
  • 15.3.4 CSL Limited
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
    • 15.3.4.3 Financials
  • 15.3.5 Dynavax Technologies
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
    • 15.3.5.3 Financials
    • 15.3.5.4 SWOT Analysis
  • 15.3.6 InvivoGen
    • 15.3.6.1 Company Overview
    • 15.3.6.2 Product Portfolio
    • 15.3.6.3 Financials
    • 15.3.6.4 SWOT Analysis
  • 15.3.7 Novavax Inc.
    • 15.3.7.1 Company Overview
    • 15.3.7.2 Product Portfolio
    • 15.3.7.3 Financials
    • 15.3.7.4 SWOT Analysis
  • 15.3.8 OZ Biosciences
    • 15.3.8.1 Company Overview
    • 15.3.8.2 Product Portfolio
  • 15.3.9 Phibro Animal Health Corporation
    • 15.3.9.1 Company Overview
    • 15.3.9.2 Product Portfolio
    • 15.3.9.3 Financials
    • 15.3.9.4 SWOT Analysis
  • 15.3.10 SEPPIC
    • 15.3.10.1 Company Overview
    • 15.3.10.2 Product Portfolio
  • 15.3.11 SPI Pharma
    • 15.3.11.1 Company Overview
    • 15.3.11.2 Product Portfolio